Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MUC1 peptide + SB-AS2
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A therapeutic vaccine composed of a 100-amino acid MUC1 peptide (corresponding to five 20-amino acid long repeats) combined with SB-AS2 adjuvant. This vaccine targets MUC1, a glycoprotein overexpressed in tumors as a hypoglycosylated form. It induces mucin-specific humoral and T-cell responses in some patients. It was tested in a Phase I clinical trial for pancreatic cancer.
- Other names
- MUC1 100mer peptide with SB-AS2 adjuvantMUC-1 100mer peptide with SB-AS2 adjuvantMUC 1 100mer peptide with SB-AS2 adjuvant
02
Targets
MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on MUC1 peptide + SB-AS2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MUC1 peptide + SB-AS2.